EHA update: Lenalidomide, bortezomib, and dexamethasone ASCT to progress for NDMM
EHA update: Lenalidomide, bortezomib, and dexamethasone ASCT to progress for NDMM
Glofitamab induces durable complete remissions in patients with relapsed large B-cell lymphoma
Time-limited venetoclax-obinutuzumab +/- ibrutnib surpasses chemoimmunotherapy in frontline chronic lymphocytic leukaemia
Quizartinib advances overall survival in acute myeloid leukaemia patients
Isatuximab, lenalidomide, bortezomib and dexamethasone as induction therapy show a superior MRD negativity rate for newly diagnosed MM patients
The abscopal effect of radiotherapy and nivolumab in relapsed or refractory Hodgkin lymphoma
UICC announces global coalition to increase access to essential cancer medicines in low and lower middle-income countries
Biomarker analysis of the NeoALTTO trial provides oncofertility insight for younger breast cancer patients
ASCO 2022: Breast cancer highlights
Updated data from the Phase 1/2 MajesTEC-1 study evaluating teclistamab, a BCMA x CD3 bispecific antibody
CheckMate 9ER: aRCC patients on nivolumab plus cabozantinib achieved deeper responses vs sunitinib
Adjuvant endocrine therapy used to treat ER+ HER2- breast cancer